Esperance Pharmaceuticals Completes $7.5 Million Series B... (ion. Esperance is using its CLYP&#...)

Esperance Pharmaceuticals Completes $7.5 Million Series B Financing

Date:6/1/2011

ion."

Esperance is using its CLYP™ technology to develop a robust portfolio of novel targeted membrane-disrupting peptides (tMDPs) to selectively destroy cancer cells that express target receptors. EP-100, the lead candidate, is designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces and is currently in a Phase 1 study in patients with advanced solid tumors. LHRH receptors are over-expressed in a wide range of human cancers including breast, prostate, endometrial, pancreatic, ovarian, skin, testicular and blood cancers. In addition to EP-100, Esperance has other drug candidates in preclinical stages of development, all of which have a unique targeting mechanism of action whereby candidates bind specifically and exclusively to surface antigens or receptors on cancer cells.

About Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is a clinical stage company developing a new class of targeted anticancer drugs using its Cationic Lytic Peptide (CLYP™) platform technology. These drug candidates, called targeted membrane-disrupting peptides (tMDPs) and antibody drug conjugates (ADCs) selectively seek and destroy cancer cells, including cells known to be resistant to chemotherapeutic drugs, without harming normal cells. Targeting occurs through binding to specific receptors and antigens on the cell's surface. The Company was founded on patented technology discovered by scientists at the Pennington Biomedical Research Center, the Louisiana State (LSU) Ag Center and LSU main campus. Founding investors include the Louisiana Fund I, Themelios Ventures and Research Corporation Technologies. Additional investors include Sanofi, Advantage Capital Partners/Louisiana Technology Fund and private investors. More information can be found at www.esperancepharma.com.

SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss

Post Your Comments:

(Date:5/24/2013)... LOS ANGELES , May 24, 2013 An ... gathered on Saturday, May 18, in Santa ... findings on new lung-sparing therapies for MPM, a rare ... and commonly affects the pleura, the lining of the ... Heart, Lung and Blood Institute, the 3rd Annual International ...

(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer"). On 20 May 2013, ...

(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...

Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2 International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 2 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3

[0] International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma [0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements [0] 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement

... 16, 2011 Cancer patients in China ... the announcement that a leading cancer center is acquiring ... VAR). This device is the first high dose rate ... leader in radiotherapy systems. Jilin University ...

... 16, 2011 U L ... announced today that it has filed an abbreviated 510(k) application ... label claim to include the management and mitigation of pain. ... a randomized clinical study comparing Altrazeal® to Acquacel® Ag in ...

Cached Medicine Technology:First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital 2 ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 2 ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 3 ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 4

First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim

(Date:5/24/2013)... The news about youth and diabetes keeps getting worse. ... that children who develop Type 2 diabetes are at high ... at a higher rate than people who acquire Type 2 ... 2 diabetes, they seem to be at very high risk ... M.D., professor of pediatric endocrinology in the School of Medicine ...

(Date:5/24/2013)... 2013 Fit Yummy Mummy, a fitness ... who are trying to get rid of the belly ... ideal for women who want to combine exercises with ... ’s Stan Stevenson, prompting an investigative review. , “Holly's ... a wide variety of motivational strategies, nutritional plans, proper ...

(Date:5/24/2013)... The Institute for Integrative Nutrition , the ... has donated $10,000 to the Cleveland Courage Fund , ... Ohio. , “When the news came out on Monday, May ... and her daughter had escaped from a Cleveland home after ... horrified,” said Integrative Nutrition Founder, Director, and Primary Teacher Joshua ...

(Date:5/24/2013)... 2013 General Data Company Inc., ... tracking and data management products and solutions, has ... Inc., (TBS) of Durham, North Carolina, a leading ... for the clinical and research pathology marketplace. TBS ... which provides specialty products and solutions to hospitals, ...

(Date:5/24/2013)... Finding the answer for this is at the centre of ... the Bergen fMRI Group at the University of Bergen (UiB) ... The way they do this is by studying people who ... mental illness. For a five-year period, the group is studying ... report published in Frontiers in Human Neuroscience shows ...

Breaking Medicine News(10 mins):Health News:Youth with type 2 diabetes at much higher risk for heart, kidney disease 2 Health News:Fit Yummy Mummy: Review Examining Holly Rigsby’s Fitness Program Released 2 Health News:Integrative Nutrition Donates $10,000 to the Cleveland Courage Fund 2 Health News:General Data Acquires Triangle Biomedical Sciences 2 Health News:General Data Acquires Triangle Biomedical Sciences 3 Health News:Help at hand for schizophrenics 2

[0] Youth with type 2 diabetes at much higher risk for heart, kidney disease [0] Fit Yummy Mummy: Review Examining Holly Rigsby’s Fitness Program Released [0] Integrative Nutrition Donates $10,000 to the Cleveland Courage Fund [0] General Data Acquires Triangle Biomedical Sciences [0] Help at hand for schizophrenics

... the 13th time, more than any hospital in the U.S. , ... ... (NorthShore) was named one of the nation,s 100 Top Hospitals® by Thomson ... and quality of healthcare. NorthShore has been named a Top 100 Hospital ...

... (April 1, 2009) It appears that a drug ... similar effect on the compulsive behavior of kleptomaniacs it ... the University of Minnesota., The Medical School,s Department of Psychiatry ... ages 17-75, who spent an average of at least one ...

... KUALA LUMPUR, Malaysia, March 31 Rheumatoid arthritis (RA) ... which the body,s defense system attacks the joints through ... lines and lubricates the joints. The most visible symptoms ... of the hands and feet. It can cause fatigue, ...

... LifeCare Holdings, Inc. (the "Company") today announced its operating ... 2008. Three Months Ended December 31, 2008 ... service revenue of $94.2 million for the three months ended ... the same period in 2007 while patient days were unchanged. ...

... Guideline Reached For Quantitative Polymerase Chain ReactionSALT LAKE CITY, ... and the American Association for Clinical Chemistry ... for a key laboratory method called qPCR (or quantitative ... international scientists representing the medical and research fields. qPCR ...

... The U.S. District Court for the District of ... between Alza Corporation, McNeil-PPC, Inc. and Andrx Pharmaceuticals LLC. ... markets CONCERTA(R) (methylphenidate HCI) Extended-Release Tablets CII, said the ... valid or infringed by the filing of Andrx,s Abbreviated ...

NorthShore University HealthSystem Named One of the Nation's Top 100 Hospitals by Thomson Reuters Drug commonly used for alcoholism, drug addiction, curbs urges of compulsive stealers Frost & Sullivan: Rheumatoid Arthritis Therapeutics in Malaysia LifeCare Holdings, Inc. Announces Year-End Results International Scientists Secure Quality in Molecular Diagnostics District Court Decision Received in CONCERTA(R) Patent Case

... Detection Of Serum C-Peptide ... Measurement:, Evaluating patients ... Assisting in the classification ... Differentiating insulin dependent patients ...

Inquire...

The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....

Inquire...

Medicine Products:

ACS:180 C-Peptide Assay C-Peptide Pach IV Pachymeter RIDASCREEN Anti-Measles Virus IgM Assay